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Abstract
Objective
To investigate if plasma HIV-1 tropism testing could identify subjects at higher risk for clinical
progression and death in routine clinical management.
Design
Nested case-control study within the EuroSIDA cohort.
Methods
Cases were subjects with AIDS or who died from any cause, with a plasma sample with
HIV-1 RNA >1000 copies/mL available for tropism testing 3 to 12 months prior to the event.
At least 1 control matched for age, HIV-1 RNA and HCV status at the time of sampling were
selected per each case. Conditional logistic regression was used to investigate exposures
associated with clinical progression to AIDS or death. A linear mixed model with random
intercept was used to compare CD4+T-cell slopes by HIV tropism over the 12 months follow-
ing the date of sampling.
Results
The study included 266 subjects, 100 cases and 166 controls; one quarter had X4 HIV; 26%
were ART-naïve. Baseline factors independently associated with clinical progression or
death were female gender (OR = 2.13 vs. male, 95CI = 1.04, 4.36), p = 0.038), CD4+T-cell
count (OR = 0.90 (95CI = 0.80, 1.00) per 100 cells/mm3 higher, p = 0.058), being on ART
(OR = 2.72 vs. being off-ART (95CI = 1.15, 6.41), p = 0.022) and calendar year of sample
[OR = 0.84 (95CI = 0.77, 0.91) per more recent year, p<0.001). Baseline tropism was not
associated with the risk of clinical progression or death. CD4+T-cell slopes did not differ
within or between tropism groups.
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Conclusions
The predictive role of plasma tropism determined using 454 sequencing in the context of
people receiving cART with detectable VL is not helpful to identify subjects at higher risk for
clinical progression to AIDS or death.
Introduction
Infection with HIV-1 with tropism for lymphocytes expressing the CXCR4 co-receptor (X4
HIV, or CXCR4-tropic HIV) [1,2] has been consistently associated with lower CD4+T-cell
counts in antiretroviral treatment (ART)-naïve and -experienced subjects [3,4], and with faster
disease progression in untreated patients [5–7], independently of their baseline CD4+T-cell
counts or HIV-1 RNA levels [8,9]. Initially, tropism assessments were based on phenotypic
assays, but such assays have limitations for clinical routine diagnostics. They are costly, time
consuming, complex and require a minimum viral load of 1000 c/ml, being unsuitable for sub-
jects with low-level viremia or those requiring CCR5 antagonists while being suppressed. Gen-
otyping approaches using V3-loop sequencing were later implemented, being faster and
cheaper [10]. Both techniques share the challenge of detecting minority virus populations that
may be clinically important.
Whereas 60 to 80% of subjects at early stages of HIV infection harbour R5 HIV, X4 viruses
emerge in approximately 50% of individuals at later stages of the disease [11,12]. In general,
tropism switches occur from R5 to X4, but occasionally X4 to R5 switches can also be seen
[13]. It has been much debated whether the emergence of X4 HIV is cause or consequence of
immune depression [14]. Using modern ultrasensitive genotyping tools, X4 HIV can be
detected in virtually any patient at very low levels shortly after HIV infection, suggesting that
X4 HIV are being contained by the immune system. Conversely, in epidemiological studies R5
to X4 tropism switches preceded CD4+ declines [15].
Advances in genotyping techniques and the availability of bioinformatic tools to accurately
predict phenotypic tropism from HIV env sequence data enable rapid, reliable and robust
assessment of HIV tropism during routine clinical management. Early phenotypic tropism
tools used to define the natural history of HIV, like the MT-2 or MT4 assays, were highly spe-
cific for X4 viruses but often lacked sensitivity and reproducibility across laboratories due to
the difficulty in establishing cell infections. Population sequencing allows streamlined process-
ing in low complexity labs and achieves an accuracy to predict the true tropism–defined as
HIV tropism determined using the enhanced-sensitivity Trofile1 assay- of around 90%, with
a sensitivity to detect X4 HIV in the range of 50-70% and specificity >90% [16]. The sensitivity
and specificity of genotypic tropism prediction in plasma are improved by using massively par-
allel deep sequencing with either 454, Illumina or any equivalent next-generation sequencing
platform [17].
Although tropism testing is mandatory before using a CCR5-inhibitor, it is uncertain
whether clinicians should order a tropism test to predict if their patients could have an
increased risk of clinical progression or if, instead, they should rely on other more classical pre-
dictors such as CD4+ counts, viral load etc. In a previous cohort study [11], subjects with X4
HIV had faster decline in CD4+ T-cell counts and suffered more clinical events over the fol-
lowing 12 months remaining off ART than those with R5 HIV. However, such differences
were no longer observed in subjects receiving antiretroviral treatment.
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The aim of this study was to determine whether, in people with detectable viral load, pres-
ence of X4 tropic HIV in plasma, determined using either population sequencing or 454 deep
sequencing, was independently associated with an increased risk of progression to AIDS or
death over the following 3 to 12 months. We also sought to evaluate in the same study popula-
tion if X4 HIV was associated with steeper declines in CD4+ counts than in people with R5
HIV. The ultimate objective of our analyses was to verify whether plasma tropism testing is
useful to predict clinical outcomes in routine HIV clinical management.
Methods
Subjects
This was a nested case-control study within the EuroSIDA cohort (described in [18]). This
study underwent an Ethics Comitee in order to assure subjects confidentiality and privacy.
The study complies with the regulations for Ethics Committee approval and procedure for
obtaining Informed Consent from participants for the EuroSIDA Study, following the Euro-
sida Study Group standards. A data collection form is completed by the sites at the time of
enrolment and every 6 months hereafter on to a standardized data collection form. From fol-
low-up Winter 2014/2015 (DS41), all data collection is in the electronic CRF system, REDCap
at https://chip-crf.info/redcap/. For each patient, the date of HIV diagnosis and way of trans-
mission is recorded. The date of diagnosis of all AIDS defining diseases are recorded, using
the 1993 Centers for Disease Control and Prevention definitions. Further, the date of starting
and stopping each antiretroviral drug is recorded, as is the use of drugs for prophylaxis against
opportunistic infections. All CD4 lymphocyte counts and viral load measurements are re-
quested at every follow-up, as well as a range of other laboratory values. Further, data about
non-AIDS defining diseases, adverse events of anti-HIV drugs (D:A:D-events), and causes of
death (CoDe) are collected. In this study, cases were subjects with an AIDS diagnosis or who
died from any cause, and who had an available plasma sample for tropism testing from the
time window of 3 to 12 months prior to the event. In sensitivity analyses we restricted to only
cases defined by AIDS or deaths due to AIDS and their matched controls. In order to minimise
the risk of sequencing failure, the available sample had to have HIV-1 RNA levels above 1,000
copies/ml. Controls were subjects from EuroSIDA who also had a plasma sample available
with HIV-1 RNA levels above 1,000 copies/ml and were AIDS-free and alive after a matched
duration of time from the date of sampling. In the original sample scheme two controls per
case were selected. Because of testing failure, some of the case-control matched set only re-
mained with one control per case. Cases and controls were matched for age (±5 years), HIV-1
RNA levels (±0.5 log) and HCV status at the time of sampling. These matching factors were
chosen because they are known to be associated with both HIV tropism and the risk of clinical
progression and unlikely to be on the causal pathway between tropism and clinical
progression.
Genotypic HIV tropism testing
HIV-1 tropism was assessed using both 454 (Roche Diagnostics, Basel, Switzerland) and popu-
lation sequencing of the V3-loop of gp120 as previously described [19]. Tropism testing was
performed blinded for case-control status and other exposures. V3-loop sequences obtained
with 454 sequencing were interpreted using the Geno2Pheno[454] algorithm. In concordance
with previous works [19–21] a sample was defined as containing X4 HIV if at least 2% of the
sequences obtained had a Geno2Pheno false-positive rate3.75%; such cutoffs showed strong
association with virological outcomes in pivotal maraviroc clinical trials. Sensitivity analyses
were also performed using a cut-off of at least 1% of the sequences obtained having a false
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positive rate of<10%, which showed the best technical correlation with Monogram1’s
Enhanced-sensitivity Trofile assay [22]. Population sequencing of the V3 loop was performed
using the TruGene1 HIV-1 Genotyping Assay (OpenGene DNA sequencing system). Tropism
was inferred from V3-loop population sequences using the Geno2Pheno[co-receptor] tool. Sam-
ples with a Geno2Pheno false-positive rate10% were considered to have X4 HIV.
Statistical analyses
Conditional logistic regression was used to investigate the association between a number of
exposure factors and the risk of clinical progression to AIDS or death. Separate logistic regres-
sion models were used for tropism estimated using 454 and population sequencing. Besides
the adjustment obtained by design for the matching factors (i.e. age, HIV viral load and HCV
Ab status), we further controlled for CD4+T-cell counts and calendar year of sample by includ-
ing these factors in the regression models.
We also compared CD4 slopes in people with R5 and X4 HIV over the 12 months following
the date of sampling using a linear mixed model with random intercept and slope using the
whole study populations of cases and controls. The difference in CD4 slope between people
carrying a X4 vs. a R5 virus was formally tested by including an interaction term in the linear
model. The linear mixed model also included gender, age, HCV co-infection, current viral
load, use of ART, mode of HIV transmission, nadir CD4+T-cell count, ethnicity and calendar
year of sample. Three separate analyses were performed: the first using all CD4+T-cell values
available per person, a second one restricted to values determined while subjects were ART-
naïve, and a third analysis using only values obtained after the date of ART initiation.
Results
Participant characteristics
A total of 300 participants (100 cases and 200 matched controls) underwent tropism testing.
Envelope amplification failed in 81 (27%) subjects for 454 sequencing, and in 104 (34%) for
population sequencing (PS). In total, this left 266 evaluable subjects, 100 were cases and 166
were controls, who were tested on a sample stored on average in 2006 (IQR: 2003–2009)
(Table 1). In a subset of 191 unique samples for which tropism could be estimated using both
454 (3.75% FPR) and population sequencing (10% FPR), 130 (68%) were concordantly classi-
fied as R5 and 30 (16%) as X4 for a kappa statistic of 55% (p<0.001). Globally, one quarter of
patients had X4 HIV (Table 1). Our study included 20% women, 47% men who have sex with
men (MSM), 92% were Caucasians and 22% had HCV co-infection. At the time of sampling,
26% were ART-naïve, 25% had begun ART but were currently off therapy and 49% were cur-
rently receiving ART. The median age, CD4+T-cell and HIV-1 RNA levels were 41 years, 350
cells/mm3 and 4.81 log c/mL, respectively. Median CD4+T-cell counts available per subject
were 3.3 counts/year (IQR = 0.7; 8.8).
Factors associated with clinical progression to AIDS and / or death
Table 2 shows the results from fitting a regression model with tropism estimated using 454
sequencing. The regression models using tropism estimated by population sequencing pro-
vided similar results (not shown). Exposures independently associated with risk of clinical
progression to AIDS and/or to death from any cause were female gender (OR = 2.13 vs. male;
95% CI = 1.04, 4.36; p = 0.038), CD4+T-cell count (OR = 0.90 per 100 cells/mm3 higher; 95%
CI = 0.80, 1.00; p = 0.058), being on ART at the time of testing (OR = 2.72 vs. being off ART;
95% CI = 1.15, 6.41; p = 0.022) and calendar year of sample (OR = 0.84 per more recent year;
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95%CI = 0.77, 0.91; p<0.001). Similar predicting factors were identified when the case defini-
tion was restricted to clinical progression and/or AIDS-related deaths (Table 2). Results were
similar when using a FPR of 10% (S1 Table). Factors associated with clinical progression to
AIDS or AIDS-related deaths were female gender (OR = 2.77 vs. male; 95% CI = 1.16, 6.63;
p = 0.022), CD4+T-cell count (OR = 0.83 per 100 cells/mm3 higher; 95% CI = 0.72, 0.96;
p = 0.012), being on ART (OR = 4.66 vs. being off ART; 95% CI = 1.56, 13.89; p = 0.006) and
calendar year of sample (OR = 0.84 per more recent year; 95%CI = 0.76, 0.93; p = 0.001). Base-
line tropism (presence of X4 HIV), either by 454 (Table 2) or population sequencing, (S2
Table) was not associated with the risk of clinical progression or death in any of the analyses
(OR = 0.66, 95% CI = 0.33, 1.33; p-value = 0.245 with the original definition of cases, or OR =
0.44, 95% CI = 0.18, 1.05; p-value = 0.064 when restricting only to deaths due to AIDS).
CD4+T-cell slopes by HIV tropism
When analyzing CD4+T-cell changes considering all available CD4 count values, we found no
statistically significant difference in CD4+T-cell count slope between X4 and R5 tropism
groups (p-value for interaction = 0.67). When considering only CD4+T-cell changes using val-
ues measured before the date of ART initiation there was a general decrease of CD4+T-cell
Table 1. Subjects’ characteristics according to 454 tropism determination.
Characteristics X4 R5 Total p-value
N = 61 N = 205 N = 266
Age, years 0.301
Median (IQR) 42 (37, 47) 41 (35, 49) 41 (36, 49)
Viral load, log10 copies/mL 0.764
Median (IQR) 4.85 (4.45, 5.29) 4.81 (4.47, 5.38) 4.81 (4.46, 5.36)
Gender, n(%) 0.135
Female 8 (13.1%) 44 (21.5%) 52 (19.5%)
Ethnicity, n(%) 0.235
White 54 (89%) 190 (93%) 244 (92%)
Asian 0 (0%) 2 (1%) 2 (1%)
Black 1 (2%) 2 (1%) 3 (1%)
Other/unknown 6 (10%) 11 (5%) 17 (6%)
Mode of HIV transmission, n(%) 0.587
Men who have Sex with Men 28 (46%) 96 (47%) 124 (47%)
Heterosexual transmission 6 (10%) 16 (8%) 22 (8%)
IDU 18 (30%) 36 (18%) 54 (20%)
Other/unknown 9 (15%) 57 (28%) 66 (25%)
CD4 count, cells/mm3 0.348
Median (IQR) 279 (150, 471) 351 (150, 530) 350 (150, 490)
HCV co-infection, n(%) 0.116
No 52 (85%) 156 (76%) 208 (78%)
Yes 9 (15%) 49 (24%) 58 (22%)
Calendar year of test 0.680
Median (IQR) 2006 (2001, 2009) 2006 (2003, 2008) 2006 (2003, 2009)
Clinical outcome, n(%) 0.559
Case 21 (34%) 79 (39%) 100 (38%)
ART-naive, n(%) 0.736
Yes 29 (48%) 102 (50%) 131 (49%)
doi:10.1371/journal.pone.0166613.t001
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Table 2. Factors associated with risk of AIDS and/or death [a) from any cause; b) related to AIDS only] from fitting a conditional logistic regres-
sion; model using 454 to infer tropism.
a) Association with risk of AIDS or death from any
cause
b) Association with risk of AIDS or death related to AIDS
only
Factor Case Control OR (95% CI) P-value Case Control OR (95% CI) P-value
N = 100 N = 166 N = 72 N = 120
Tropism (454 estimatec), n
(%)
R5 79 (79.0%) 126 (75.9%) 1.00 59 (81.9%) 89 (74.2%) 1.00
X4 21 (21.0%) 40 (24.1%) 0.66 (0.33,
1.33)
0.245 13 (18.1%) 31 (25.8%) 0.44 (0.18,
1.05)
0.064
Gender, n(%)
Male 75 (75.0%) 139 (83.7%) 1.00 50 (69.4%) 105 (87.5%) 1.00
Female 25 (25.0%) 27 (16.3%) 2.13 (1.04,
4.36)
0.038 22 (30.6%) 15 (12.5%) 2.77 (1.16,
6.63)
0.022
Aged, years
Median (IQR)d 40 (35, 48) 42 (36, 50) 41 (35, 50) 42 (36, 51)
Viral loadd, log10
copies/mL
Median (IQR) 4.83 (4.44,
5.25)
4.81 (4.48,
5.38)
4.80 (4.44,
5.31)
4.78 (4.48,
5.38)
CD4+T-cell counta,
cells/mm3
Median (IQR) 285 (132, 417) 357 (201, 548) 0.90 (0.80,
1.00)
0.058 289 (141, 416) 381 (242, 559) 0.83 (0.72,
0.96)
0.012
ART use, n(%)
Not started 20 (20.0%) 49 (29.5%) 1.00 11 (15.3%) 40 (33.3%) 1.00
Started, currently on ART 31 (31.0%) 35 (21.1%) 2.72 (1.15,
6.41)
0.022 20 (27.8%) 19 (15.8%) 4.66 (1.56,
13.89)
0.006
Started, currently off ART 49 (49.0%) 82 (49.4%) 1.42 (0.65,
3.09)
0.381 41 (56.9%) 61 (50.8%) 2.67 (0.96,
7.39)
0.059
Co-infection with HCVd, n
(%)
No 77 (77.0%) 131 (78.9%) 64 (88.9%) 110 (91.7%)
Yes 23 (23.0%) 35 (21.1%) 8 (11.1%) 10 (8.3%)
Mode of HIV transmission,
n(%)
Homosexual contacts 42 (42.0%) 82 (49.4%) 1.00 24 (33.3%) 27 (22.5%) 1.00
IVDU 21 (21.0%) 33 (19.9%) 1.16 (0.47,
2.90)
0.745 10 (13.9%) 17 (14.2%) 1.31 (0.40,
4.31)
0.652
Heterosexual contacts 10 (10.0%) 12 (7.2%) 0.91 (0.32,
2.58)
0.859 8 (11.1%) 10 (8.3%) 1.18 (0.36,
3.92)
0.781
Other/unknown 27 (27.0%) 39 (23.5%) 1.84 (0.86,
3.97)
0.117 24 (33.3%) 27 (22.5%) 2.54 (1.07,
6.03)
0.035
CD4+T-cell count nadira, n
(%)
Median (IQR) 174 (58, 289) 202 (55, 360) 1.06 (0.84,
1.34)
0.642 201 (58, 301) 204 (56, 362) 1.21 (0.90,
1.61)
0.202
Calendar year of sampleb
Median (IQR) 2004 (2002,
2006)
2007 (2004,
2010)
0.84 (0.77,
0.91)
< .001 2004 (2003,
2006)
2007 (2005,
2010)
0.84 (0.76,
0.93)
0.001
Ethnicity, n(%)
White 90 (90.0%) 154 (92.8%) 1.00 64 (88.9%) 109 (90.8%) 1.00
(Continued)
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count in both tropism groups but again with no difference in mean slope (-96 cells/mm3/year
(95% CI: -325, 133) in people carrying X4 viruses vs. -158 (-283, -34) cells/mm3/year in the R5
group, p = 0.64, Table 3). Similarly, in the analysis using CD4+T-cell values measured after the
date of ART initiation, as expected, CD4+T-cell counts showed an increase, which again was
no different according to tropism (+36 cells/mm3/year in the X4 HIV group vs. +59 in R5
group, p = 0.67). In addition, there was no evidence that the difference in slope between X4
and R5 tropism varied by ART status (interaction p-value = 0.26), suggesting that the lack of
association was consistent regardless of ART use (Table 3).
Discussion
In this study we have compared the difference in risk of short-term (3–12 months) progression
to AIDS/death between people carrying predominantly R5 or X4 viruses, taking into account
CD4+T-cell count and use of ART. Plasma HIV-1 tropism, regardless of how estimated, did
not predict the short-term risk of the composite outcome of AIDS or death over 3–12 months
from the date of sample, after controlling for co-infection with HCV, age, current viral load,
CD4 count and calendar year. CD4+T-cell slopes were not significantly different between tro-
pism groups, and there was no evidence that this difference varied when separately considering
Table 2. (Continued)
a) Association with risk of AIDS or death from any
cause
b) Association with risk of AIDS or death related to AIDS
only
Factor Case Control OR (95% CI) P-value Case Control OR (95% CI) P-value
N = 100 N = 166 N = 72 N = 120
Non white 10 (10.0%) 12 (7.2%) 1.02 (0.35,
2.92)
0.976 8 (11.1%) 11 (9.2%) 0.85 (0.26,
2.80)
0.784
Drug resistance, n(%)
None 65 (65.0%) 131 (78.9%) 1.00 47 (65.3%) 96 (80.0%) 1.00
1 class 35 (35.0%) 35 (21.1%) 1.31 (0.63,
2.73)
0.476 25 (34.7%) 24 (20.0%) 1.34 (0.54,
3.32)
0.527
Data adjusted for matching factors, CD4+T-cell count and calendar year of sampling.
aOR per 100 cells/mm3 higher.
bOR per more recent year.
cDeclared X4 if 2%of minority population when using a 3.75% FPR.
dMatching factor.
doi:10.1371/journal.pone.0166613.t002
Table 3. Interaction between effects of tropism and ART status on CD4 slope from fitting a linear mixed model with random intercept and slope.
X4& R5 Difference X4 vs. R5
Period Mean CD4 count change*
(95% CI)
p-value Mean CD4 count change*
(95% CI)
p-value Mean CD4 count change*
(95% CI)
p-value
All periods -10 (-104, 83) 0.830 11 (-46, 69) 0.701 -21 (-120, 77) 0.670
Periods before starting
ART
-96 (-325, 133) 0.414 -158 (-283, -34) 0.014 63 (-198, 323) 0.638
Periods after starting
ART
36 (-62, 134) 0.468 59 (-2, 119) 0.057 -23 (-125, 80) 0.666
(Interaction p-value for the difference by tropism (X4 vs. R5) between the periods before starting ART and after starting ART = 0.26).
&Declared X4 if2% of minority population when using a 3.75% FPR, by 454.
*per year.
doi:10.1371/journal.pone.0166613.t003
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treated and untreated subjects. It is important to point out that when we used an alternative
case definition including only deaths due to AIDS, results were similar, although the analysis
had less statistical power. We have obtained the same results using 454 sequencing and popula-
tion sequencing (PS), which may indicate that the lack of association between tropism and
clinical progression in our study was not due to lack of sensitivity when detecting low-fre-
quency X4 HIV.
One limitation of the analysis of the comparison of the CD4 count slopes is the low statisti-
cal power when stratifying subjects in tropism groups and on/off ART, as in some of the sub-
populations we have few subjects. Analyses took into consideration factors known to be associ-
ated with risk of AIDS progression, such as age at diagnosis, mode of HIV transmission, nadir
CD4+T-cell count, sex and ethnicity [23–25]. Prior studies have also reported positive and neg-
ative associations between specific human leucocyte antigen (HLA) alleles and the rate of
HIV-1 disease progression [26,27]. We did not evaluate the role of HLA in clinical progression
in our analysis because conclusive studies regarding the influence of HLA on HIV-1 and, in
general, on infectious diseases require large number of samples, ethnicity stratification, precise
clinical information and consideration of other known genetic effects on the disease.
Besides the clinical binary end-point assessed in the case-control analysis we also evaluated
CD4+T-cell count variations over time because this measure has been a central predictor of
HIV disease progression and death, has been the main means to evaluate suitability for treat-
ment initiation [28,29] and is used by the World Health Organization (WHO) to define disease
staging [30]. Tropism was not associated with differences in CD4 slopes, neither before nor
after starting ART.
In our analysis, tropism was measured in plasma, so patient selection was conditioned by
the fact that participants had to have a VL of at least 1000 c/mL to minimize the risk of
sequencing failure and having missing data for tropism. Therefore, among people who cur-
rently had a detectable viral load, we were comparing the risk of events in those who, at the
time of the stored sample, had started ART with those who were still ART-naïve. The most
likely explanation of our finding is the presence of confounding by indication as, for a given
high viral load, ART is typically initiated in people with lower CD4 count and with a higher
risk of AIDS and death. Although the estimates are adjusted for CD4+ T-cell count we cannot
rule out the presence of residual confounding. In addition, EuroSIDA does not collect the data
of HIV seroconversion and therefore the time spent with HIV is a plausible unmeasured con-
founder that we could not control for.
Lack of amplification was not uncommon, and this might be attributable to the highly vari-
able sequence of the envelope gene. Another possibility is that due to the small volumes in
PCR reactions it is possible that stochastically, no viral molecules were taken, as viral loads
were not high in many cases. We performed analysis of the predictors of amplification failure
using a logistic regression. The two independent predictors of amplification failure were HIV
subtype (48% failure in non B-virus vs. 29% in B virus, p<0.0001) and lower level of viral load
(mean VL 4.60 log10 copies/mL in amplifications failures vs. 4.78 log10 copies/mL in successful
amplifications, p = 0.04) (S3 Table). Because viral load is also moderately associated with clini-
cal progression it is possible that some selection bias was introduced. This is somewhat inevita-
ble in analysis involving retrospective amplification of PCR as amplification is difficult at low
levels of viremia.
For 454 sequencing we used the FPRs values recommended at the time of the analysis (e.g.
3.75% and 10%), but results were similar when using a FPR of 10%. Some retrospective re-
analyses of pre-treatment plasma samples from maraviroc trials in ART-naïve and ART-expe-
rienced subjects showed that 454 sequencing and/or population sequencing for tropism infer-
ence were able to predict virological response to maraviroc as accurately as Trofile and ESTA.
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For Sanger sequencing, we used a FPR of<10%, which is the recommended by the guidelines,
because we wanted to have results that could be applicable to clinical practice.
We defined short term as a period of 3–12 months because data from the literature show
that AIDS and death in natural history appear to occur relatively quickly after the switch from
a R5 to X4 virus. Therefore we designed the nested case-control analysis to evaluate the short-
term risk. Also, the cross-sectional nature of the study design does not allow to control effec-
tively for potential time-dependent confounders. Thus, by evaluating the short-term risk we
wanted to try to protect the results from this other important source of bias.
Ideally, people with undetectable viral load could also be included and tropism estimated
using proviral DNA. However, the number of clinical events in people with suppressed viral
load would likely be very small and therefore a much larger study population would be needed
to show any differences, if they existed. Moreover, the degree of clinical validation of genotypic
tropism tests in clinical trials, at least in relation to response to CCR5 antagonists, is by far
much stronger in plasma than in PBMCs [21].
Whether subjects with X4 HIV have impaired CD4+ T-cell count recovery during ART
remains unclear. Some studies reported poorer CD4+T-cell count recovery in virologically
suppressed ART-treated subjects with X4 HIV relative to individuals with R5 HIV [5,31]. In a
large cohort study in London, subjects with dual/mixed or X4 HIV had faster CD4+ T-cell
count declines than those with R5 HIV in the absence of ART. However, CD4+T-cell count
increases, time to viral suppression and rates of viral suppression over 2-years were similar
between groups in treated subjects [11]. In a study characterizing the viral and host factors
influencing rapid HIV progression [32], higher virus replicative capacity and CXCR4 corecep-
tor usage were closely linked to faster CD4+T-cell depletion and rapid disease progression. In a
previous analysis conducted by some of us, subjects with late presentation and<100 CD4+T-
cell counts at HIV diagnosis who had X4 HIV by 454 sequencing at baseline, had significantly
lower CD4+T-cell counts than those infected with an R5 HIV and showed an impaired
CD4+T-cell counts recovery over the ensuing two years of ART [19]. Discrepancies between
results in different studies may be due to the heterogeneity of the populations that are being
studied (e.g. differences in viral load and CD4+T-cell counts at study entry, use of antiretrovi-
rals and duration of follow-up).
We found that calendar year of sample was a factor independently associated with the risk
of clinical progression or death (16% risk reduction per more recent year). This may be
explained due to the improvements in the clinical management of the patients, differences in
the actual drugs used, recent regimens typically being more efficacious with a better toxicity
profile and easier to take than in the past.
Being a woman in this population also meant to have increased risk of progression to AIDS
or death (almost a 3–fold increased risk compared to men). It has been previously reported
from studies in Europe that women have higher rates of virological failure and increased rates
of discontinuation of treatment [33,34]. Of note, however, the effect of gender in our study
was independent of HIV-1 RNA and CD4 count. Women tend to be HIV-diagnosed later than
men who have sex with men (MSM) [35], which likely reflects barriers on access to care. Addi-
tionally, in the UK, for example, HIV infected women have different origins, ethnicities and
socioeconomic status, compared to HIV positive men[36]. Another factor independently asso-
ciated with the risk of progression was current use of ART. Although the OR might appear to
go in the opposite direction of that expected (higher risk in treated vs. not treated) this could
be explained by confounding by indication, given the conducted analysis, as those subjects on
ART and with a viral load1000 copies/ml are actually going towards a virological failure.
In conclusion, our results suggest that the predictive role of plasma tropism determined
using 454 sequencing in the context of people receiving cART with detectable VL is not helpful
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to identify subjects at higher risk for clinical progression after controlling for age, plasma HIV
viral load and HCV serostatus. Clinicians should rather consider gender, CD4+ counts and
virological outcomes of ART for that purpose. Further studies are needed to evaluate the role
of tropism testing in proviral DNA to predict clinical progression to AIDS and/or death.
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